Effects of Highly Absorptive Curcumin on Impaired Glucose Tolerance

Effects of Highly Absorptive Curcumin on Impaired Glucose Tolerance - Curcumin on IGT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007361

Enrollment

Registered

2012-02-22

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IGT

Interventions

High-absorption curcumin with DDS (Theracurmin, 1 capsule: 30 mg) at a fixed daily dose of 6 capsules/day. Placebo at a fixed daily dose of 6 capsules/day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with impaired glucose tolerance or type 2 diabetes, in whom HbA1c values between 6.3 and <8.4% (No history of insulin treatment within 1 year before registration)

Exclusion criteria

Exclusion criteria: 1) insulin therapy 2) renal insufficiency (Cre >= 4.0mg/dL) or hemodialysis 3) severe hepatic disorder or liver chirrosis 4) Unstable angina pectoris, acute myocardial infarction, severe coronary heart disease (left main trunk or triple vessel disease) 5) Shock, Heart failure, myocardila infarction, Pulmonary embolism 6) Stroke within 3 months 7) Severe ketosis, diabetic coma or pre-coma 9) Malneutrition 10) Malignancy 11) Anemia 12) Steroid use

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Countries

Japan

Contacts

Public ContactKoji Hasegawa

National Hospital Organization Kyoto Medical Center Division of Translational Research

koj@kuhp.kyoto-u.ac.jp075-641-9161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026